Criteria and regulatory considerations for the conditional approval of innovative antitumor drugs in China: from the perspective of clinical reviewers

Affiliations

¹ Office of Clinical Evaluation 1, Center for Drug Evaluation, National Medical Products Administration, Beijing 100022, P. R. China.
² Office of Management and Communication, Center for Drug Evaluation, National Medical Products Administration, Beijing 100022, P. R. China.
³ Harbin Institute of Hematology and Oncology, Harbin 150010, Heilongjiang, P. R. China.

Editorial

Limin Zou et al. Cancer Commun (Lond). 2023 Feb.

. 2023 Feb;43(2):171-176.

doi: 10.1002/cac2.12400. Epub 2023 Jan 22.

¹ Office of Clinical Evaluation 1, Center for Drug Evaluation, National Medical Products Administration, Beijing 100022, P. R. China.
² Office of Management and Communication, Center for Drug Evaluation, National Medical Products Administration, Beijing 100022, P. R. China.
³ Harbin Institute of Hematology and Oncology, Harbin 150010, Heilongjiang, P. R. China.

No abstract available

Figures

1. SCPRC . Opinions on the Reform of the Examination and Approval System of Pharmaceutical and Medical Devices. Beijing. 2015.
1. NMPA . Measures for the Administration of Drug Registration. Beijing. 2020.
1. NMPA . Review Procedures for Breakthrough Therapy Drugs (Trial). Beijing. 2020.
1. Zou LM, Du Y, Qi YL, Tang L, Yang ZM. Considerations on granting breakthrough therapy designation in oncology. Chin J Clin Pharmacol. 2021;37(11):1471‐1475.
1. NMPA . Review and Approval Procedures for Conditional Approval of Drugs (Trial). Beijing. 2020.